Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.16
Bid: 5.82
Ask: 6.50
Change: -0.35 (-5.38%)
Spread: 0.68 (11.684%)
Open: 6.51
High: 0.00
Low: 0.00
Prev. Close: 6.51
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of New Chief Financial Officer

11 Oct 2023 07:00

RNS Number : 6997P
Synairgen plc
11 October 2023

Synairgen plc

('Synairgen' or the 'Company')

Appointment of Joseph Colliver as New Chief Financial Officer

Southampton, UK - 11 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces that Joseph Colliver has been appointed Chief Financial Officer (CFO) and Executive Director with effect from Monday 6 November 2023. In conjunction with this appointment, and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO and Executive Director on Friday 3 November.

Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies.

Richard Marsden, CEO of Synairgen, said: "Joseph's many years of listed company experience, including in the healthcare sector, will stand us in good stead as we progress towards the clinic with our SNG001 strategy. I'd like to thank John for his steadfast commitment, loyalty and support to both me and the Board over many years. We wish him the very best for the future."

Joseph Colliver, newly appointed CFO of Synairgen, commented: "This is a pivotal time for the Company, as it works towards the next phase of clinical trials with SNG001. I look forward to working closely with Richard and the team in the coming months and years."

John Ward, outgoing CFO of Synairgen, commented: "It has been a pleasure to work with the Synairgen team for these many years, driven by the shared vision to develop treatments for severe viral lung infections. However, it's the right time to pass on the baton, and I look forward to following the Company's next steps and wish the team every success with SNG001 in the future."

Information required under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies ("AIM Rules")

Full name:

Joseph Tregonning Colliver

Age:

43

Shares held in the Company:

None

Current directorships:

· Phytome Life Sciences Plc

· Phytome Research Ltd

· Hellenic Dynamics Plc

· Psych Capital Plc

· Colliver Advisory Ltd

Historic directorships in previous 5 years:

· Sativa Wellness Group Inc

· Borganic Consulting Inc

· Olimax NT Sp z o.o.

· Sativa Group Ltd

· Blood Matters Ltd

· Sativa Cultivation and Extraction Limited

· Sativa Wellness Ltd

· Phytovista Laboratories Ltd

· Goodbody Botanicals Ltd

· Tessellate Collective Ltd

· Goodbody and Blunt Ltd

· Sativa Investments Ltd

· Goodbody Wellness Limited

· George Botanicals Ltd

· Sativa Cosmetics Ltd

There is no further information to be disclosed in relation to the appointment pursuant to Rule 17 and Schedule Two, paragraph (g) of the AIM Rules.

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

Synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOABIBDGLUBDGXG
Date   Source Headline
25th Jan 20217:00 amRNSInclusion in US ACTIV-2 trial
20th Jan 20217:00 amRNSHome trial recruitment completed
13th Jan 20217:00 amRNSFirst Patient Dosing in Phase III SG018 Trial
6th Jan 20215:10 pmRNSHolding(s) in Company
5th Jan 20215:53 pmRNSHolding(s) in Company
18th Dec 20207:00 amRNSCOVID-19 Clinical Programme Update
10th Dec 202012:57 pmRNSHolding(s) in Company
13th Nov 20205:03 pmRNSHolding(s) in Company
13th Nov 20207:00 amRNSLancet Respiratory Medicine publishes Phase 2 data
10th Nov 20201:47 pmRNSHolding(s) in Company
4th Nov 20205:51 pmRNSHolding(s) in Company
3rd Nov 20209:00 amRNSHolding(s) in Company
2nd Nov 202012:20 pmRNSResult of General Meeting and Total Voting Rights
2nd Nov 20207:00 amRNSResult of Open Offer
28th Oct 202011:20 amRNSHolding(s) in Company
27th Oct 20208:35 amRNSHolding(s) in Company
21st Oct 20209:45 amRNSHolding(s) in Company
21st Oct 20209:40 amRNSHolding(s) in Company
16th Oct 20203:10 pmRNSExercise of Options and Total Voting Rights
15th Oct 20205:35 pmRNSExercise of Options and Total Voting Rights
15th Oct 20201:51 pmRNSDirector/PDMR Shareholding
15th Oct 20207:00 amRNSResults of Placing
14th Oct 20205:32 pmRNSPlacing and Open Offer
12th Oct 202011:05 amRNSSecond Price Monitoring Extn
12th Oct 202011:00 amRNSPrice Monitoring Extension
6th Oct 20208:55 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSAppointment of Joint Broker
1st Oct 20202:06 pmRNSSecond Price Monitoring Extn
1st Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 202011:00 amRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSClinigen signs MAP agreement with Synairgen
29th Sep 20207:00 amRNSSynairgen and Clinigen sign Managed Access Program
29th Sep 20207:00 amRNSInterim results for six months ended 30 June 2020
9th Sep 20207:00 amRNSSynairgen IP Update
8th Sep 20207:00 amRNSPositive interim analysis of SNG001 in COPD
7th Sep 20203:53 pmRNSHolding(s) in Company
3rd Sep 20205:58 pmRNSHolding(s) in Company
1st Sep 20204:41 pmRNSSecond Price Monitoring Extn
1st Sep 20204:36 pmRNSPrice Monitoring Extension
24th Aug 20204:41 pmRNSSecond Price Monitoring Extn
24th Aug 20204:36 pmRNSPrice Monitoring Extension
21st Aug 20205:28 pmRNSHolding(s) in Company
13th Aug 20204:41 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:57 amRNSHolding(s) in Company
10th Aug 20209:50 amRNSHolding(s) in Company
7th Aug 20208:22 amRNSHolding(s) in Company
5th Aug 20205:51 pmRNSHolding(s) in Company
31st Jul 20208:37 amRNSHolding(s) in Company
29th Jul 20204:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.